Skip to content
lsd.com
CompletedPhase 4Results posted

Anhedonia, Development, and Emotions: Phenotyping and Therapeutics

NCT05487885 · ADEPT · Erika Forbes

Closed to entry
Status
Not accepting participants
Phase 4
Phase
123
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

The goal of the ADEPT Study is to understand anhedonia in young people and how it changes based on treatments targeting the brain circuit underlying it. Anhedonia is a challenging mental health symptom that involves difficulty with motivation to experience pleasant events. This study could help develop treatments for people whose depression does not improve with traditional treatments. The ADEPT Study includes two phases. In Phase 1, participants are asked to go through a series of activities to measure anhedonia, including MRI scans, blood draws, behavioral tasks, clinical interviews, questionnaires, and app-based assessments of experiences and behaviors. Phase 2 involves therapeutic activities, such as transcranial magnetic stimulation (TMS), positive affect training, and, for some people, ketamine administration. If the participant qualifies and is interested, they may choose to do Phase 2 activities in addition to Phase 1.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Montgomery-Asberg Depression Rating Scale (MADRS) Score

    Measured over pre- to post-TMS (over 2 weeks) and pre- to post-ketamine (24 hours)

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

15 Years to 25 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: Phase 1 (all participants) * Current DSM-5 depressive disorder * Severity ≥ 12 on MADRS * Moderate-severe anhedonia (75% of sample) or low anhedonia (25% of sample) Phase 2 (for participants in TBS and ketamine phase, in addition to above) • ≥ 1 failed antidepressant trial (for qualification for Phase 2 of study and definition of non-response to TMS in order to be eligible for ketamine) = Treatment for at least 6 weeks with an antidepressant medication reaching recommended dosage for adults for at least 3 weeks of the treatment (e.g., 20 mg fluoxetine) Exclusion Criteria: Phase 1 (all participants) * Lifetime psychosis, bipolar disorder, or developmental disorder * Serious, unstable neurological disorder (e.g., seizure disorder) * Brain injury with loss of consciousness * Moderate-severe substance use disorder, past 6 mos. * MRI contraindications (e.g., metal in body) Phase 2 (for participants in TBS and ketamine phase, in addition to above) * Serious, unstable respiratory or cardiovascular illness * Pre-TBS: Alcohol binge in past week or \> 3 drinks/day in past 3 days * Pre-ketamine: use of MAOIs in past 2 weeks * Pregnancy * High blood pressure * Current illicit stimulant use * Lifetime recreational ketamine or PCP use

Where

1 study site

FacilityCityRegionCountry
Loeffler BuildingPittsburghPennsylvaniaUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT05487885 on ClinicalTrials.gov →

Last updated in the registry 2026-03-17. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

Recruiting in